Orexo ABORXOF 34 1-Year ROIIC % is -102.55 as of Mar. 2026. GuruFocus rates ORXOF with a GF Score™ of 34/100 and a GF Value™ of $0.68 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 968 Drug Manufacturers companies, Orexo AB ranks worse than 87.4% on this metric.
1-Year Return on Invested Incremental Capital (1-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 1-year.
Orexo AB's 1-Year ROIIC % for the quarter that ended in Mar. 2026 was -102.55%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Orexo AB's 1-Year ROIIC % or its related term are showing as below:
ORXOF's 1-Year ROIIC % is ranked worse than 87.4% of 968
companies
in the Drug Manufacturers industry
Industry Median: 1.315
vs ORXOF: -102.55
Orexo AB (OTCPK:ORXOF) 1-Year ROIIC % Explanation
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Orexo AB 1-Year ROIIC % Related Terms
Orexo AB 1-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Orexo AB's 1-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Orexo AB's 1-Year ROIIC %, along with its competitors' market caps and 1-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Orexo AB 1-Year ROIIC % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Orexo AB's 1-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Orexo AB's 1-Year ROIIC % falls into.
Orexo AB's 1-Year ROIIC % for the quarter that ended in Mar. 2026 is calculated as:
1-Year ROIIC %
=
1-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
1-Year Incremental Invested Capital
=
( -23.4676 (Mar. 2026) - -26.1816 (Mar. 2025) )
/
( 33.422 (Mar. 2026) - 36.515 (Mar. 2025) )
=
2.714
/
-3.093
=
-87.75%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** TTM data of NOPAT and Invested Capital was used to calculate 1-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Orexo AB (ORXOF) has a 1-Year ROIIC % of -102.55 as of Mar. 2026. 1-Year ROIIC % measures the change in earnings as a percentage of change in investment over 1-year. View historical data on Orexo AB and its competitors. According to the industry distribution chart, Orexo AB ranks #846 out of 968 companies in the Drug Manufacturers industry, placing it in the top 87.4%.
Is Orexo AB's 1-Year ROIIC % too high?
Orexo AB's current 1-Year ROIIC % is -102.55. Based on the distribution chart, Orexo AB ranks #846 out of 968 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Orexo AB has a GF Score™ of 34/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Orexo AB's 1-Year ROIIC % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Orexo AB ranks #846 out of 968 companies for 1-Year ROIIC %. This places Orexo AB in the lower half of its industry. The industry median 1-Year ROIIC % is 1.32. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 1-Year ROIIC % for a Drug Manufacturers company?
The median 1-Year ROIIC % among Drug Manufacturers companies is 1.32, based on 968 companies in the industry. Companies in the top quartile (top 25%) have a 1-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 1-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 1-Year ROIIC % mean?
A high 1-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 1-Year ROIIC % measures the change in earnings as a percentage of change in investment over 1-year. View historical data on Orexo AB and its competitors. For the Drug Manufacturers industry, the median 1-Year ROIIC % is 1.32 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Orexo AB's current 1-Year ROIIC % is -102.55. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Orexo AB stock overvalued right now?
Based on GuruFocus' analysis, Orexo AB (ORXOF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.68, compared to a current price of $2.10 — trading 208.8% above its estimated fair value. The current 1-Year ROIIC % is -102.55. Orexo AB's overall GF Score™ is 34/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 1-Year ROIIC % calculated?
1-Year ROIIC % is calculated from a company's financial statements. For Orexo AB (ORXOF), the current 1-Year ROIIC % is -102.55 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Orexo AB (ORXOF) Overvalued in 2026?
Based on GuruFocus' analysis, Orexo AB stock appears to be overvalued.
The current stock price of $2.10 is trading 208.8% above its estimated GF Value™ of $0.68.
GuruFocus considers Orexo AB to be Significantly Overvalued.
Key valuation signals for ORXOF:
1-Year ROIIC %: -102.55
GF Value™: $0.68 vs. price of $2.10 (208.8% above fair value)
No single metric tells the full story. See the ORXOF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Orexo AB is a Swedish pharmaceutical company dedicated to advancing treatments for severe diseases and life-saving rescue medications to meet future healthcare needs, developing improved medications based on proprietary drug delivery technologies. At the core of its innovation is AmorphOX, which improves bioavailability and stability for both large and small molecules. It has developed four drugs from concept to approval, including Zubsolv, Abstral, Edluar, and Diabact UBT. The company's current development efforts focus on AmorphOX, with projects in preclinical and clinical phases across multiple therapeutic areas. It operates through US Commercial and HQ & Pipeline, which generate maximum revenue, and operates in the US, EU, and UK generating maximum revenue, and the Rest of the World.
34GF Score
Get the complete analysis for ORXOF
1-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ORXOF has been successfully added to your 
